Ulcerative Colitis
FDA grants orphan drug designation to pouchitis treatment derived from green tea
The FDA has granted orphan drug designation to PharmassêtX’s PSX-514, a drug derived from an active component of green tea, for the treatment of pouchitis, according to a company press release.
FDA approves biosimilar Pyzchiva for all approved Stelara indications
The FDA has approved the Stelara biosimilar Pyzchiva for psoriatic arthritis, Crohn’s disease and all other indications approved for the reference medicine, according to a press release from Sandoz.
Hormone replacement therapy improves IBD symptoms in postmenopausal women
Hormone replacement therapy was associated with improved disease symptoms, measured by the physician global assessment score, in a cohort of postmenopausal women with inflammatory bowel disease, according to data.
Skyrizi snags FDA approval for moderate to severe UC; first IL-23 approved for UC, CD
The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn’s disease, AbbVie reported.
VIDEO: Studies show no increased risk of cancer, CV events with JAK inhibitors
In this video, Raymond Cross, MD, spoke with Healio about several studies assessing the safety and efficacy of JAK inhibitors in patients with IBD presented at Digestive Disease Week 2024.
VIDEO: ‘Big year’ for IL-23 inhibitors in trials for ulcerative colitis
In this Healio video, Uma Mahadevan, MD, director of the Colitis and Crohn’s Disease Center at the University of California, San Francisco, discusses new study results assessing the use of interleukin-23 inhibitors in ulcerative colitis.
Patients ‘continue to respond’ to subcutaneous Skyrizi despite failed IV induction in UC
WASHINGTON — A maintenance dose of subcutaneous Skyrizi may still induce clinical response in patients with ulcerative colitis who failed to achieve response after 12 weeks of IV induction, noted a presenter at Digestive Disease Week.
‘Promise of lasting efficacy’: Guselkumab outperforms placebo, ustekinumab in Crohn’s
WASHINGTON — In patients with active Crohn’s disease, guselkumab was superior to both placebo and standard-of-care ustekinumab after 48 weeks of treatment, according to late-breaking data from the phase 3 GALAXI program.
Evolocumab shows particular CV benefit in those with autoimmune disease, inflammation
Patients with atherosclerosis and elevated LDL plus autoimmune or inflammatory disease may derive particular CV benefit from PCSK9 inhibition with evolocumab, a speaker reported.
Entyvio effective in pediatric IBD, ‘should be included in our treatment paradigm’
WASHINGTON — Entyvio is “safe and effective” for maintaining sustained steroid-free remission at 1 year in children with inflammatory bowel disease, more so in those with ulcerative colitis vs. Crohn’s disease, according to a researcher.